On August 11, 2022, Frontier Biotechnologies (Nanjing) Co., Ltd. (hereinafter referred to as Frontier Biotech or Company, stock code: 688221. SH), and Shanghai Pharmaceutical Group (stock code: 601607. SH, 02607.HK) Keyuan Xinhai (Beijing) Medical Supplies Trading Co., Ltd. (hereinafter referred to as Keyuan Trading) signed a commercialization cooperation agreement for Aikening^® (generic name: Labuvirtide), the world's first long-acting HIV-1 fusion inhibitor. This collaboration facilitates sales and academic education through multi-dimensional strategies in China.